Inventor · disambiguated record
Viktoria Gusarova
Also filed as: GUSAROVA VIKTORIA
16 granted patents·19 pending applications·130 citations·filing 2010–2025
91Inventor score
Top patents by PatentIndex Score
35 records- 0198US9018356B2Anti-ANGPTL3 antibodies and uses thereofSLEEMAN MARK W·Filed 2012·Granted Apr 28, 2015·86 cites·12 claims
- 0291US10995150B2Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibodyREGENERON PHARMA·Filed 2019·Granted May 4, 2021·6 cites·19 claims
- 0391US9951127B2Anti-ANGPTL3 antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Apr 24, 2018·7 cites·5 claims
- 0490US2025136675A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0588US9120851B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2012·Granted Sep 1, 2015·11 cites·11 claims
- 0686US2025066463A1Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0785US10494442B2Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9REGENERON PHARMA·Filed 2014·Granted Dec 3, 2019·9 cites·20 claims
- 0884US10358487B2Anti-ANGPTL3 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Jul 23, 2019·2 cites·10 claims
- 0983US2022403016A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1082US10259870B2Anti-ANGPTL8 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Apr 16, 2019·2 cites·3 claims
- 1181US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 1281US8354103B2Human antibodies to human angiopoietin-like protein 4REGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·5 cites·6 claims
- 1380US2022153825A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1477US2025171622A1Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1577US2025075216A1Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1677US2025129366A1Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1776US2022127348A1Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1875US2020377583A1Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitorREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 1974US2023345919A1Non-human animals comprising a humanized asgr1 locusREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2073US10442856B2Methods of treating obesity with anti-ANGPTL8 antibodiesREGENERON PHARMA·Filed 2017·Granted Oct 15, 2019·1 cites·10 claims
- 2172US2022089711A1Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3REGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2269US2019315851A1Anti-angptl3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2368US12497460B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·30 claims
- 2466US12209180B2Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonistsREGENERON PHARMA·Filed 2019·Granted Jan 28, 2025·0 cites·45 claims
- 2562US11696572B2Non-human animals comprising a humanized ASGR1 locusREGENERON PHARMA·Filed 2018·Granted Jul 11, 2023·0 cites·25 claims
- 2661US12281173B2Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitorREGENERON PHARMA·Filed 2020·Granted Apr 22, 2025·0 cites·25 claims
- 2761US2024207204A1Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) AgonistsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2860US2020079841A1Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3REGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2957US2017291937A1Methods for Treating Hyperlipidemia with an ANGPTL8 Inhibitor and an ANGPTL3 InhibitorREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3053US2017233466A1Methods for Treating or Preventing Atherosclerosis by Administering an Inhibitor of ANGPTL3REGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3152US2018244801A1Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9REGENERON PHARMA·Filed 2018·Application pending·0 cites
- 3251US11977081B2ANGPTL8 assay and uses thereofREGENERON PHARMA·Filed 2018·Granted May 7, 2024·0 cites·13 claims
- 3350US2025388890A1ASS1 Gene Insertion For The Treatment Of Citrullinemia Type IREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3447US2017253666A1Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 InhibitorREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3545US10582702B2Non-human animals having an engineered ANGPTL8 geneREGENERON PHARMA·Filed 2017·Granted Mar 10, 2020·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Viktoria Gusarova files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →